Patients with severe COVID-19 pneumonia treated with leukotriene inhibitors are more likely to survive (Common, cheap asthma drugs helped 13.5% - 22% more patients survive)

Medical Xpress / University at Buffalo / Journal of Clinical and Translational Science ^ | May 25, 2022 | Ellen Goldbaum / Peter L. Elkin et al

[ConservativeMind]

Biomedical informatics researchers have found that patients hospitalized with COVID-19 pneumonia had a 13.5% survival advantage when treated with a combination of leukotriene inhibitors (LTIs) and the steroid dexamethasone.

The study shows that patients with low oxygen saturations who are treated with leukotriene inhibitors in addition to dexamethasone have a 13.5% inpatient survival advantage in COVID 19 infection. Patients on LTIs prior to hospitalization who were continued on their LTI had a 22% survival advantage.

…"This represents a new treatment with very strong results and when implemented, should save lives broadly," said Elkin.

The 13.5% survival advantage was found in severely ill patients presenting with oxygen saturation of 50% or less.

The researchers also found that treating severely ill COVID-19 patients with dexamethasone alone did not have any beneficial effect on mortality or morbidity.

"I knew that IL6 and IL8 (interleukin 6 and 8) were bad prognostic indicators in ARDS," said Elkin. "I also knew leukotriene inhibitors decrease these inflammatory mediators, so we hypothesized that they may be useful in decreasing mortality and morbidity in COVID-19 pneumonia."

Patients treated with LTIs had lower rates of inflammation and the "cytokine storm" seen in COVID-19 pneumonia.

Patients in the study who had asthma, and who were found to be at higher risk for severe outcomes from COVID-19 did better when treated with LTIs and dexamethasone than did patients with asthma who weren't treated with these drugs.

Elkin noted that patients who were being treated with the combination of LTIs and dexamethasone were in general more compromised than patients who weren't treated with this combination.

"This makes it likely that our finding of 13.5% improved survival is an underestimate of the true effect, as the LTI users were in general had more comorbidities than the patients who weren't treated with LTIs," he said.

[bunkerhill7]

I yam totally stupid about asthma drugs.

[metmom]

I was on Singulair for a while.

I did try Advair, but because it’s a steroid, it gave me oral thrush. YUCK!!!!!!!!!

[Harmless Teddy Bear]

Funny but when the medical people actually treat people with WuFlu with the standard treatment for respiratory infection they tend to live.

When they give them a Tylenol (never tested for use in treating WuFlu) and send them home to get worse and die, they die.

Do you find that interesting?

Because as someone who been treated for years for lung problems I find the new way simply fascinating.

It used to be listen to lungs, write prescription for medication.

Now it is listen to lungs, send to get test, don't actually bother to read test, decide that presumptive positive (no virus present but is coughing) means person has WuFlu, do not treat.

[wastedyears]

Or the Zelenko protocol.